RE: NCYT30 Sep 2021 10:02
"Announces 6 month delays for their LFT approvals"
Did you note the reason for the delay.......This delay is due to increased demand for self-test approvals causing a backlog of tests currently under review by the Company's Notified Body. The Notified Body has communicated a delay of up to six months, therefore, the Company is also evaluating other approved options for a COVID-19 self-LFT.
AND
Further to the announcement on 23 April 2021, Novacyt's PathFlow® SARS-CoV-2 SMART IgG LFT, expected to launch in Q3 2021, is also delayed. This is due to the "Company's partner" being unable to secure sufficient supplies for Novacyt to launch the test. Novacyt is, therefore, evaluating additional LFT options to detect and differentiate between SARS-CoV-2 IgG antibodies.
the Company's partner???? Who will this be and could ODX step in and do the job.